FONTANA DILETTA

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio

Zapata Dongo, R., Poterico, J., Fontana, D., Mologni, L., Alvarez-Chacon, C., Rojas-Armas, J., et al. (2025). An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer. FRONTIERS IN PHARMACOLOGY, 16 [10.3389/fphar.2025.1605314]. Dettaglio

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante Varillas, S. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. PLOS ONE, 20(1) [10.1371/journal.pone.0308747]. Dettaglio

Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. Intervento presentato a: Under 40 in Hematology. Giovani ematologi a confronto, Milano, Italia. Dettaglio

Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa [10.1158/1538-7445.AM2024-4885]. Dettaglio